Veracyte Q2 Revenues up 71 Percent; Agrees to Amend Genyzme Deal | GenomeWeb

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Wednesday that its revenues for the second quarter increased 71 percent year over year, but still fell short of the consensus analysts' estimate.

It also said that it and Genzyme have agreed to amend their co-promotion agreement reached in early 2012.

The South San Francisco, Calif.-based firm said that for the three months ended June 30, revenues reached $8.7 million, compared to $5.1 million in the year-ago period. On average, Wall Street had expected revenues of $9.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.

Sponsored by
HTG Molecular

This webinar will discuss potential clinical applications for miRNA signatures and a novel, extraction-free miRNA profiling technology for advancing biomarker discovery. 

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.